Determination of the Concentration of IgG against the Spike Receptor-Binding Domain That Predicts the Viral Neutralizing Activity of Convalescent Plasma and Serum against SARS-CoV-2

Several hundred millions of people have been diagnosed of coronavirus disease 2019 (COVID-19), causing millions of deaths and a high socioeconomic burden. SARS-CoV-2, the causative agent of COVID-19, induces both specific T- and B-cell responses, being antibodies against the virus detected a few day...

Descripción completa

Detalles Bibliográficos
Autores: Santiago, Llipsy, Uranga-Murillo, Iratxe, Arias, Maykel, González-Ramírez, Andrés M., Macías-León, Javier, Moreo, Eduardo, Redrado, Sergio, García-García, Ana, Taleb, Víctor, Lira-Navarrete, Erandi, Hurtado-Guerrero, Ramón, Aguilo, Nacho, del Mar Encabo-Berzosa, Maria, Hidalgo, Sandra, Galvez, Eva M., Ramirez-Labrada, Ariel, de Miguel, Diego, Benito, Rafael, Miranda, Patricia, Fernández, Antonio, Domingo, José M., Serrano, Laura, Yuste, Cristina, Villanueva-Saz, Sergio, Paño-Pardo, José R., Pardo, Julián
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Institución:Universidad de Zaragoza
Repositorio:Zaguán. Repositorio Digital de la Universidad de Zaragoza
OAI Identifier:oai:zaguan.unizar.es:101576
Acceso en línea:http://zaguan.unizar.es/record/101576
Access Level:acceso abierto
Descripción
Sumario:Several hundred millions of people have been diagnosed of coronavirus disease 2019 (COVID-19), causing millions of deaths and a high socioeconomic burden. SARS-CoV-2, the causative agent of COVID-19, induces both specific T- and B-cell responses, being antibodies against the virus detected a few days after infection. Passive immunization with hyperimmune plasma from convalescent patients has been proposed as a potentially useful treatment for COVID-19. Using an in-house quantitative ELISA test, we found that plasma from 177 convalescent donors contained IgG antibodies specific to the spike receptor-binding domain (RBD) of SARS-CoV-2, although at very different concentrations which correlated with previous disease severity and gender. Anti-RBD IgG plasma concentrations significantly correlated with the plasma viral neutralizing activity (VN) against SARS-CoV-2 in vitro. Similar results were found using an independent cohort of serum from 168 convalescent health workers. These results validate an in-house RBD IgG ELISA test in a large cohort of COVID-19 convalescent patients and indicate that plasma from all convalescent donors does not contain a high enough amount of anti-SARS-CoV-2-RBD neutralizing IgG to prevent SARS-CoV-2 infection in vitro. The use of quantitative anti-RBD IgG detection systems might help to predict the efficacy of the passive immunization using plasma from patients recovered from SARS-CoV-2.

Similares en LA Referencia